検索結果

General Announcement: July 8, 2024 Senju Pharmaceutical Co., Ltd. Notice of Orphan Drug Designation for SJP-0008 as a Treatment of Central Retinal Artery Occlusion Senju Pharmaceutical Co., Ltd. (Head...

esident: Mr. Naoyuki Mochida; hereinafter: Mochida) and developed by Senju as an eye drop treatment for Dry Eye Disease (DED), has been launched in Japan today. Avarept® represents a novel therapy for...

NewMytear A | OTC Products, etc. | Products | SENJU Pharmaceutical

sium, and calcium was made closer to normal tears. This medicine contains calcium that is important for maintaining the function and transparency of the cornea. pH, osmotic pressure ratio, and viscosi...

esident: Mr. Naoyuki Mochida; hereinafter: Mochida) and developed by Senju as an eye drop treatment for Dry Eye Disease (DED), has been launched in Japan today. Avarept® represents a novel therapy for...

Compliance System | Our Initiatives for Society/Environment | About Senju | SENJU Pharmaceutical

Code of Conduct for Compliance The directors, employees and other members of Senju Pharmaceutical Co., Ltd. (“SENJU”) will act in compliance not only with the law but will operate under a high standar...